(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types … Continued
Total investment in the field now over $65 million New York, NY February 11, 2015 — To conclude Ovarian Cancer Research Fund’s 20th anniversary year, $6.453 million has been awarded … Continued
(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational … Continued
(February 4, 2014) In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy. The work … Continued
(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer. The … Continued
(Feb. 2, 2015) Recent studies have suggested that ovarian cancer predominantly arises within the fallopian tubes or the uterus. A group of Swedish researchers hypothesized that surgical removal of the fallopian … Continued
(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr. … Continued
(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment … Continued
(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to … Continued
The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will … Continued
A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative … Continued
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly … Continued
Get email updates about research news, action alerts, and ways to join the fight.
